<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03601897</url>
  </required_header>
  <id_info>
    <org_study_id>DCC-2036-01-003</org_study_id>
    <nct_id>NCT03601897</nct_id>
  </id_info>
  <brief_title>A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deciphera Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deciphera Pharmaceuticals LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination&#xD;
      with paclitaxel designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in&#xD;
      patients with advanced or metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 19, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (Part 1 and Part 2)</measure>
    <time_frame>Approximately 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR) (Part 2)</measure>
    <time_frame>Approximately 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of rebastinib</measure>
    <time_frame>Cycle 1 Day 1, Cycle 1 Day 15 (each cycle is 28 days)</time_frame>
    <description>Measure the Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC) of rebastinib</measure>
    <time_frame>Cycle 1 Day 1, Cycle 1 Day 15 (each cycle is 28 days)</time_frame>
    <description>Measure the AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free-survival (PFS)</measure>
    <time_frame>Approximately 36 months</time_frame>
    <description>Measure of the time from Cycle 1 Day 1 to disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>Approximately 36 months</time_frame>
    <description>Measure of the time from Cycle 1 Day 1 to the first documentation of progressive disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Approximately 36 months</time_frame>
    <description>Measure of time from PR, CR to disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Approximately 36 months</time_frame>
    <description>Measure of overall survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">201</enrollment>
  <condition>Locally Advanced or Metastatic Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Part 1 - Completed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose comparison between 50 or 100 mg BID of rebastinib orally (PO) in combination with paclitaxel administered by IV infusion at 80 mg/m2 in repeated 28-day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose expansion in the following tumor types at the recommended Phase 2 dose (RP2D) of rebastinib in combination with paclitaxel&#xD;
Triple-negative and Stage IV inflammatory breast cancer&#xD;
Ovarian cancer&#xD;
Endometrial cancer&#xD;
Gynecological Carcinosarcoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rebastinib</intervention_name>
    <description>25 mg tablets or 75 mg tablets</description>
    <arm_group_label>Part 1 - Completed</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
    <other_name>DCC-2036</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel administered by IV infusion at 80 mg/m2</description>
    <arm_group_label>Part 1 - Completed</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients ≥18 years of age at the time of informed consent.&#xD;
&#xD;
          2. Part 1 Histologically confirmed diagnosis of a locally advanced or metastatic solid&#xD;
             tumor for which paclitaxel is considered appropriate treatment.&#xD;
&#xD;
          3. Part 2&#xD;
&#xD;
               -  Triple-negative and Stage IV inflammatory breast cancer.&#xD;
&#xD;
               -  Recurrent ovarian cancer.&#xD;
&#xD;
               -  Recurrent, metastatic or high-risk endometrial cancer.&#xD;
&#xD;
               -  Advanced (stage III or IV), or recurrent gynecological carcinosarcoma&#xD;
&#xD;
                    -  Homologous or heterologous type carcinosarcoma (malignant mixed Mullerian&#xD;
                       tumor [MMMT] allowed&#xD;
&#xD;
          4. ECOG PS of ≤2.&#xD;
&#xD;
          5. Able to provide an archival tumor tissue sample&#xD;
&#xD;
          6. Adequate organ function and bone marrow reserve&#xD;
&#xD;
          7. If a female of childbearing potential, must have a negative pregnancy test prior to&#xD;
             enrollment.&#xD;
&#xD;
          8. Patient must provide signed consent to participate in the study and is willing to&#xD;
             comply with study-specific procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received prior anticancer or other investigational therapy within 28 days or 5× the&#xD;
             half-life prior to the first dose.&#xD;
&#xD;
          2. Not recovered from prior-treatment toxicities to Grade ≤1.&#xD;
&#xD;
          3. Peripheral neuropathy of any etiology &gt;Grade 1.&#xD;
&#xD;
          4. Concurrent malignancy.&#xD;
&#xD;
          5. Known active CNS metastases.&#xD;
&#xD;
          6. Use of systemic corticosteroids.&#xD;
&#xD;
          7. Known retinal neovascularization, macular edema or macular degeneration.&#xD;
&#xD;
          8. History or presence of clinically relevant cardiovascular abnormalities.&#xD;
&#xD;
          9. QTcF &gt;450 ms in males or &gt;470 ms in females.&#xD;
&#xD;
         10. Left ventricular ejection fraction (LVEF) &lt;50% at screening.&#xD;
&#xD;
         11. Arterial thrombotic or embolic events.&#xD;
&#xD;
         12. Venous thrombotic event.&#xD;
&#xD;
         13. Active infection ≥Grade 3.&#xD;
&#xD;
         14. HIV or HCV infection only if taking medications excluded per protocol, active HBV, or&#xD;
             active HCV infection.&#xD;
&#xD;
         15. Use of proton pump inhibitors.&#xD;
&#xD;
         16. If female, the patient is pregnant or lactating.&#xD;
&#xD;
         17. Major surgery 4 weeks prior to the first dose of study drug&#xD;
&#xD;
         18. Malabsorption syndrome or other illness which could affect oral absorption.&#xD;
&#xD;
         19. Known allergy or hypersensitivity to any component of rebastinib or any of its&#xD;
             excipients.&#xD;
&#xD;
         20. Any other clinically significant comorbidities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver- Anschutz Medical Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Clinical Research Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health/Monter Cancer Center</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women &amp; Infants Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants- Texas Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 5, 2018</study_first_submitted>
  <study_first_submitted_qc>July 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rebastinib</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>breast cancer</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>endometrial cancer</keyword>
  <keyword>gynecological carcinosarcoma</keyword>
  <keyword>malignant mixed Mullerian tumor (MMMT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Rebastinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

